- Home
- ZBIO vs ITIC Comparison
ZBIO vs ITIC Comparison
Compare ZBIO & ITIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZBIO
- ITIC
- Stock Information
- Founded
- ZBIO 2019
- ITIC 1972
- Country
- ZBIO United States
- ITIC United States
- Employees
- ZBIO N/A
- ITIC N/A
- Industry
- ZBIO
- ITIC Specialty Insurers
- Sector
- ZBIO
- ITIC Finance
- Exchange
- ZBIO NYSE
- ITIC Nasdaq
- Market Cap
- ZBIO 389.2M
- ITIC 440.1M
- IPO Year
- ZBIO 2024
- ITIC N/A
- Fundamental
- Price
- ZBIO $9.80
- ITIC $194.51
- Analyst Decision
- ZBIO Strong Buy
- ITIC
- Analyst Count
- ZBIO 7
- ITIC 0
- Target Price
- ZBIO $32.29
- ITIC N/A
- AVG Volume (30 Days)
- ZBIO 131.3K
- ITIC 81.9K
- Earning Date
- ZBIO 05-15-2025
- ITIC 05-08-2025
- Dividend Yield
- ZBIO N/A
- ITIC 0.94%
- EPS Growth
- ZBIO N/A
- ITIC 18.56
- EPS
- ZBIO N/A
- ITIC 15.69
- Revenue
- ZBIO $15,000,000.00
- ITIC $261,197,999.00
- Revenue This Year
- ZBIO N/A
- ITIC N/A
- Revenue Next Year
- ZBIO N/A
- ITIC N/A
- P/E Ratio
- ZBIO N/A
- ITIC $12.75
- Revenue Growth
- ZBIO N/A
- ITIC 15.27
- 52 Week Low
- ZBIO $5.83
- ITIC $167.22
- 52 Week High
- ZBIO $26.25
- ITIC $290.40
- Technical
- Relative Strength Index (RSI)
- ZBIO N/A
- ITIC 25.69
- Support Level
- ZBIO N/A
- ITIC $228.21
- Resistance Level
- ZBIO N/A
- ITIC $235.99
- Average True Range (ATR)
- ZBIO 0.00
- ITIC 8.57
- MACD
- ZBIO 0.00
- ITIC -5.52
- Stochastic Oscillator
- ZBIO 0.00
- ITIC 0.34
About ZBIO ZENAS BIOPHARMA INC
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.
About ITIC Investors Title Company
Investors Title Co operates in the title insurance and exchange services sectors. The title insurance segment, conducted through ITIC and NITIC, offers title insurance policies for residential, commercial, and industrial properties in around 22 states and the District of Columbia, with a focus on the eastern United States. The title insurance segment issues title insurance policies through approved attorneys from underwriting offices and through independent issuing agents. Title insurance policies insure titles to real estate.n The Title Insurance segment contributes the majority of the company's revenue.